Risperdal Consta – Long-term Acting Injections in the Treatment of Schizophrenia and Schizoaffective Disorders: Preliminary 12-Month Results of the Project e-STAR in the Czech and Slovak Republics

Česká verzia

Authors: I. Tůma ¹; J. Pečeňák ²; P. Mohr ³; E. Češková ⁴; M. Anders ⁵
Authors place of work: Psychiatrická klinika LF UK a FN, Hradec Králové ¹; Psychiatrická klinika LF UK a FN, Bratislava ²; Psychiatrické centrum Praha a Psychiatrická klinika 3. LF UK, Praha ³; Psychiatrická klinika LF MU a FN, Brno ⁴; Psychiatrická klinika 1. LF UK a VFN, Praha ⁵
Published in the journal: Čes. a slov. Psychiat., 104, 2008, No. 2, pp. 59-67.
Category: Original Article

Summary

E-STAR is an international, long-term, prospective, observational study of patients with schizophrenia and schizoaffective disorder switched to treatment with Risperidone Consta long acting injection (Consta). Data are collected both retrospectively for a period of 1 year and prospectively every 3 months up to 2 years. This interim analysis presents results of a group of 280 patients who have completed one-year prospective treatment with Risperdal Consta in the Czech and Slovak Republics. Long-acting risperidone reduced relapse rates and need for hospital services and increased the rate of symptomatic remission during the first year. Treatment with Consta injection was associated with improvement of activities of daily living and overall clinical global improvement. Moreover, Consta significantly reduced suicidal tendencies and violent behavior. The proportion of patients treated with combination of antipsychotics has decreased, compared with the retrospective one-year period. Long-acting risperidone has the potential to improve adherence to the antipsychotic treatment in patients suffering from schizophrenia and schizoaffective disorder. E-STAR project provides important information about the pharmacological treatment of schizophrenia and schizoaffective disorder in a usual clinical practice setting.

Key words:
schizophrenia, schizoaffective disorder, risperidone long acting injection, maintenance treatment, adherence.

Zdroje

1. American Psychiatric Association: Diagnostic and Statistical Manual. Fourth Edition. Washington DC, American Psychiatric Assoc., 1994, p. 32.

2. Adams, C. E., Fenton, M. K. P., Auraishi, S., David, A. S.: Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry, 179, 2001, pp. 290-299.

3. Andreasen, N. C., Carpenter, W. T. Jr., Kane, J. M., Lasser, R. A., Marder, S. R., Weinberger, D. R.: Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry, 162, 2005, pp. 441-449.

4. Adams, C E, Fenton, M. K., Quraishi, S., David, A. S.: Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry, 179, 2001, pp. 290-299.

5. Češková, E.: Nové trendy v léčbě schizofrenie. Psychiat. pro praxi, 9, 2008, s. 40-43.

6. Češková, E., Přikryl, R., Kašpárek, T., Kučerová, H.: Nedostatek náhledu a nonkompliance a jejich vzájemný vztah u schizofrenie. Čes. a slov. Psychiat., 103, 2007, s. 336-340.

7. Fleischhacker, W. W., Eerdekens, M., Karcher, K., Remington, G., Llorca, P. M., Chrzanowski, W., Martin, S., Gefvert, O.: Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry, 64, 2003, pp. 1250-1257.

8. Gerlach, J.: Depot neuroleptik in relace preventiv: advantages and disadvantages. Int.Clin. Psychopharmacol., 9, 1995 (Suppl. 5), pp. 17-20.

9. Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., Jeste, D. V.: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry, 161, 2004, pp. 692-699.

10. Guy, W.: Clinical global Impression. ECDEU assessment manual for psychopharmacology. Rockville (MD): U.S. Department of Health and Human Services, 1976.

11. Chue, P., Eerdekens, M., Augustyns, I., Lachaux, B., Molcan, P., Eriksson, L., Pretorius, H., David, A. S.: Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol., 15, 2005, pp. 111-117.

12. Kane, J. M.: Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotik: clinical studies. J. Clin. Psychiatry, 64, 2003 (Suppl. 16), pp. 34-40.

13. Kane, J. M., Eerdekens, M., Lindenmayer, J. P., Keith, S. J., Lesem, M., Karcher, K.: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J., Psychiatry, 160, 2003, pp. 1125-1132.

14. Kane, J. M.: Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J. Clin. Psychiatry, 67, 2006 (Suppl. 5), pp. 9-14.

15. Kissling, W.: Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiat. Scand., 89, 1994( Suppl.), pp. 16-24.

16. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., Hsiao, J. K.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 353, 2005, pp. 1209-1223.

17. McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., Strakowski, S. D.: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry, 164, 2007, pp. 1050-1060.

18. Olivares, J. M., Peuskens, J., Pecenak, J., Tuma, I., van Koten, M., Eriksson, L., Povey, M., Lam, A., Zhao, Z. on behalf of the e-STAR study group: Treatment retention with Risperidone Long Acting Injection (RLAI) in European patients with schizophrenia: 12-month interim results from the electronic schizophrenia treatment adherence registry (e-STAR). 10th European Congress, Dublin, Ireland, 20-23 October 2007.

19. Olivares, J. M., Rodriguez-Morales, A., Diels, J., Lam, A., Zhao, Z. on behalf of the e-STAR study group: 24 months treatment discontinuation rates in patients with schizophrenia treated with Risperidone Long Acting Injection (RLAI) versus oral antipsychotics: results from the electronic schizophrenia treatment adherence registry (e-STAR) in Spain. 10th European Congress, Dublin, Ireland, 20-23 October 2007.

20. Rabin, C., Liang, Y., Ehrlichman, R. S., Budhian, A., Metzger, K. L., Majewski-Tiedeken, C., Winey, K. I., Siegel, S. J.: In vitro and in vivo demonstration of risperidone implants in mice. Schizophrenia Res., 98, 2008, pp. 66-78.

21. Remington, G. J., Adams, M. E.: Depot neuroleptic therapy: clinical considerations. Can. J. Psychiatry, 40, 1995, pp. S5-S11.

22. Schooler, N. R.: Relapse and rehospitalization: comparing oral and depot antipsychotics. J. Clin. Psychiatry, 64 (Suppl. 16), 2003, pp. 14-17.

23. Siegel, S. J., Winey, K. I., Gur, R. E., Lenox, R. H., Bilker, W. B., Ikeda, D., Gandhi, N., Zhang, W. X.: Surgical implantable long-term antipsychotic delivery system for the treatment of schizophrenia. Neuropsychopharmacology, 26, 2002, pp. 817-823.

24. Simpson, G. M., Mahmoud, R. A., Lasser, R. A., Kujawa, M., Bossie, C. A., Turkoz, I., Rodriguez, S., Gharabawi, M.: A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry, 67, 2006, pp. 1194-1203.

25. Švestka, J.: Prvé antipsychotikum 2. generace v depotní formě: risperidon mikrosféry v intramuskulárních injekcích. Psychiatrie, 6, 2002, s. 261-267.

26. Tiihonen, J., Walhbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J. P., Volavka, J., Haukka, J.: Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ, 333, 2006, pp. 224-229.

27. Walburn, J., Gray, R., Gournay, K., Quraishi, S., David, A. S.: Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br. J. Psychiatry, 179, 2001, pp. 300-307.

28. Weiden, P. J., Kozma, C., Grogg, A., Locklear, J.: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr. Serv., 55, 2004, pp. 886-891.

Štítky

Addictology Paediatric psychiatry Psychiatry

Článek Results of a Detailed Observation Concerning Application of Coercive Measures during Hospitalization – the EUNOMIA Project, Results in the Czech Republic

Článok vyšiel v časopise

Czech and Slovak Psychiatry

2008 Číslo 2

Najčítanejšie tento týždeň

Najčítanejšie v tomto čísle